Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.
May 28, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Taysha Gene Therapies and maintained a $7 price target.
The reiteration of an Overweight rating and the maintenance of a $7 price target by a reputable analyst can boost investor confidence in Taysha Gene Therapies, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100